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PROCDIM is a valuable tool to capture several patients reported outcomes and data
for chronic disease management. Such tools could be used for collecting data for
disease management, clinical trial and for observational studies for various
chronic diseases.
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VALIDATING AN ALTERNATIVE WEIGHTING ALGORITHM OF THE CHARLSON
COMORBIDITY INDEX (CCI) FOR RISK ADJUSTMENT IN PREVIOUSLY
HOSPITALIZED PATIENTS
Cheng LI, Rascati KL
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OBJECTIVES: To validate an alternative weighting algorithm of the Charlson Co-
morbidity Index (CCI) for the prediction of health care expenditures and utilization
in previously hospitalized patients.METHODS:Data from the Medical Expenditure
Panel Survey (MEPS) Panel 12 (2007-2008) were retrieved for this retrospective co-
hort study. Two CCI scores were calculated for patients who were hospitalized in
2007: one based on the original weights (Charlson-CCI) and the other based on the
weights updated by Quan et al. (Quan-CCI) [both were developed to predict mor-
tality]. Adjusted R2 from linear regression models were used to estimate log-trans-
formed healthcare expenditures (COST) in 2008. Odds ratios and c statistics from
logistic regression models were used to compare the predictive power of the risk of
hospitalizations ( 1 admission), risk of emergency department visits ( 1 visit),
and high expenditures ( 90th percentile of COST) in 2008. RESULTS: Seven hun-
dred patients who had been previously hospitalized were included in the study.
The mean (SD) age was 52.5 (15.3) years, and 65% were female. In the linear regres-
sions, the Charlson-CCI explained more variance in COST than the Quan-CCI (ad-
justed R2  20.7% vs. 19.9%), adjusting for age and sex. The Charlson-CCI was a
better predictor of the risk of emergency department visits (c0.600) than the
Quan-CCI (c0.571). Compared with the Quan-CCI, the Charlson-CCI showed bet-
ter discriminatory power for the prediction of high-expenditure individuals
(c0.770 vs. 0.743) and the risk of hospitalizations (c0.589 vs. 0.581). The Quan-CCI
did not significantly predict high-expenditure individuals (OR1.15; 95% CI0.99-
1.33) or the risk of hospitalizations (OR1.14; 95% CI0.99-1.30). CONCLUSIONS: In
a group of previously hospitalized patients, the original CCI exhibited better dis-
crimination for the prediction of healthcare expenditures, hospitalizations, and
emergency department visits. The weights updated by Quan et al. were developed
to predict mortality and may have limited utility in predicting health care utiliza-
tion.
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USING PROBABALISTIC SENSITIVITY ANALYSIS IN BUDGET IMPACT MODELS
TO REDUCE UNCERTAINTY AND IMPROVE DECISION-MAKING
Latif F, Roberts G
Double Helix Consulting, London, UK
OBJECTIVES: Budget impact analysis (BIA) is formally required by many national
HTA regulatory agencies including NICE and the PBAC, in the UK and Australia,
respectively. Current practice only involves the use of point estimates to serve as
“best guess” for decision-makers. However, using probabilistic sensitivity analysis
(PSA) can serve to reduce parameter uncertainty in order to generate discussion
and ultimately improve decision-making. METHODS: Using the same techniques
applied to cost-effectiveness analysis, a PSA was incorporated into a budget impact
model used for a client’s medical device. This involved creating and running a
Monte-Carlo simulation (MCS) over 10,000 iterations to generate a 95% confidence
interval (CI) around the overall budget impact in addition to a probability curve.
RESULTS: Point-estimate budget impact was found to be a saving of £4,736,893
based on a number of pre-defined input parameters in the model. Running a MCS
generated a 95% CI: a saving of £10,367,403 and an incremental cost of £861,166
either side of the point-estimate. In addition, a probability curve was generated
with overall budget impact on the x-axis and probability on the y-axis. 25 data
points were generated running from a maximum potential saving of approxi-
mately £12m (1% probability) to an incremental cost of approximately £3m (100%
probability). CONCLUSIONS: Using PSA in this budget impact model demonstrates
that there is a significant likelihood this medical device could actually generate an
incremental cost rather than saving (which the point-estimate shows). This serves
as an example of how using this technique could serve to generate discussion
among decision-makers in order to make more informed and improved budget
impact decisions in the future.
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COULD CORPORATE SOCIAL RESPONSIBILITY PREDICT PHARMACEUTICAL
CORPORATE FINANCIAL PERFORMANCE?
Auamnoy T, Areepium N
Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: 1) To quantify CSR concept by developing a pharmaceutical compa-
nies namely Auamnoy’s visual analogue scales—a 24 measurement indicators in 6
dimensions to make a composite variate; 2) To perform a retrospective research to
explore relationship between CSR activities and corporate financial performance
(CFP); and 3) To discover prediction model to predict pharmaceutical CFP by CSR.
METHODS: Challenging literature reviews were executed on and on to find the
valid and reliable scales to measure CSR. Twelve appropriate CFP indicators were
discussed and then selected to evaluate 43 pharmaceutical companies perfor-
mance. The  value was set at 0.05, one side using SPSS version 17.0 to calculate all
statistical analysis. RESULTS: The six dimensions Auamnoy’s scales were Drug
development, Patients, Environment and safety, Social issues, Philanthropy and
Business ethics and – yielded acceptable Cronbach’s alpha 0.7415, 0.7154, 0.7151,
0.7426, 0.7217 and 0.7466 respectively. Pearson’s product moment correlation con-
firmed that CSR showed a significant positive correlated with (ROI, Sales, EPS, DPS,
BV, %Sales Growth, %ROA and %ROI) (r0.832, 0.489, 0.789, 0.631, 0.351,
0.298,0.455,0.336, p0.000, 0.000, 0.000, 0.000, 0.011, 0.030, 0.001, 0.008 respec-
tively). Finally, Regression analysis estimated significant seven models of pharma-
ceutical CFP–ROI, Sales, EPS, DPS, BV, %ROA and %ROI by CSR. CONCLUSIONS: The
answer was yes, pharmaceutical CSR could predict CFP. The more the pharmaceu-
tical companies invested in CSR. the more CFP they obtained.
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OBJECTIVES: There is a wealth of literature and guidance available for cost-effec-
tiveness research, but the guidance available on budget impact analysis (BIA) is less
familiar to many investigators. In times of increased budget constraint, however,
the importance and popularity of BIA is growing. The objective of this review was to
assess whether guidance on BIA methodology is available and consistent.
METHODS: Online searches were performed to identify published guidelines or
recommendations on BIA from any country. The guidelines were then reviewed for
whether they gave advice on certain pre-determined methodological categories.
RESULTS: National guidelines have been produced in Canada, Ireland, Scotland
and Poland specifically on how BIA in each of these countries should be performed.
Other countries such as the UK, Italy and Hungary include recommendations on
BIA within guidelines on health care economic assessment, but their focus is
largely on cost-effectiveness analysis. The national guidelines were consistent in
whether they made recommendations on perspective and time horizon, but varied
in whether they gave advice on market share determination, sources of costs,
inclusion of treatment of adverse events and the presentation of resource use and
costs separately. The definition of the term ‘incremental BIA’ was also used incon-
sistently. An ISPOR Task Force has produced international guidance for budget
impact methodologies, which is designed to support national guidelines rather
than supersede them and also to improve consistency across BIAs developed for
different settings. CONCLUSIONS: Several national and international bodies have
developed guidelines or tools for developing and reporting budget impact models.
However, different specifications exist and not all methodological aspects are
made explicit in every case. Consensus guidelines such as those produced by the
ISPOR task force are required to shape future national BIA recommendations.
PRM10
TO GET THE RIGHT PRICE – A DECISION SUPPORT METHOD TO OPTIMIZE
MANAGERIAL DECISIONS ON PUBLIC FUNDING PRICE TO APPLY FOR
Wilk NM1, Kloc K2
1Arcana Institute, Krakow, Malopolskie, Poland, 2Arcana Institute, Krakow, malopolskie, Poland
OBJECTIVES: In challenging economic times public funding decision makers are
getting tougher, so the managers have to be smarter to choose the right price and
optimally justify it. The objective is to present our method which rationally sup-
ports managerial decisions on pricing in public funding. METHODS: The decision
support method consists of the following steps: 1) identify all arguments relevant
to different price levels – e.g. based on prices of similar drugs that were accepted by
public payer or related to prices of the drug in other countries; 2) calculate maxi-
mum price that may be justified with each piece of an argument; 3) sort arguments
in price ascending order; 4) rank arguments in a pairwise manner against their
impact on probability of public funding acceptance using 5-point Likert scale; 5)
plot all arguments on a graph with price level on X axis and cumulative impact on
probability of acceptance on Y axis; and 6) calculate first derivative to identify local
maxima. The seventh step is the manager’s decision on choosing the right price
from the subset of local maxima. Local maxima represent the price levels for which
a relatively large increase in price associates with a relatively small decrease in
acceptance for public funding. RESULTS: The decision support analysis results in a
subset of price levels that the manager is recommended to choose the right price
from. The final choice may depend on acceptance/avoidance of risk or necessity to
achieve a specific turnover. All arguments that justify the chosen and higher prices
may be used to justify this price to public funding decision makers.CONCLUSIONS:
To ensure a pricing success to their companies and their own career development
Market Access managers should use the presented decision support method to
make possibly best informed choices concerning official prices of their drugs.
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LEARNING EFFECT IN ECONOMIC EVALUATIONS OF HEALTH CARE
INTERVENTIONS
Chang S, Sungher D, Diamantopoulos A
Symmetron Limited, Elstree, Herts, UK
OBJECTIVES:The presence of the learning effect has an impact on the effectiveness
of health technologies and so, it is relevant to capture this in an economic analysis.
The aim of this study is to explore the bibliography of learning curves in health care
economic evaluations. METHODS: In order to understand the bibliography of
learning curves in economic evaluations, a systematic review was conducted to
identify economic analyses that include a formal description of a learning effect.
The following databases were searched: Medline, Medline (R), Embase, EconLIT,
HEED and NHS EED. For a study to be included in the review, it had to be an
economic evaluation defined as a cost, utility or cost-effectiveness study. In addi-
tion, the study also had to formally analyse the learning effect by using statistical
analysis, graphs or tables. All non-human and non-English studies were also ex-
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